CSIMarket Company Name, Ticker, Suppliers, else..
 
Aligos Therapeutics Inc   (NASDAQ: ALGS)
 
Price: $5.8600 $-1.05 -15.195%
Day's High: $6.8196001052856445 Week Perf: -21.55 %
Day's Low: $ 5.86 30 Day Perf: 38.53 %
Volume (M): 98,111 52 Wk High: $ 13.69
Volume (M$): $ 0 52 Wk Avg: $7.64
Open: $6.82 52 Wk Low: $3.98



 Market Capitalization (Millions $) 61
 Shares Outstanding (Millions) 10
 Employees 82
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -90
 Cash Flow (TTM) (Millions $) -44
 Capital Exp. (TTM) (Millions $) 0

Business Description


Aligos Therapeutics Inc is a pharmaceutical company focused on developing innovative treatments for viral infections and liver diseases. The company is dedicated to addressing the unmet medical needs in these areas by utilizing cutting-edge science and research. Aligos Therapeutics aims to provide effective and safe therapies to patients around the world by leveraging its expertise in virology and liver biology. The company's mission is to improve the lives of those affected by viral infections and liver diseases through groundbreaking drug development and clinical research.


   Company Address: One Corporate Drive South San Francisco 94080 CA
   Company Phone Number: 466-6059   Stock Exchange / Ticker: NASDAQ ALGS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -3.15%    
GILD   -0.27%    
IOVA        1.36% 
MRNA        1.04% 
SRZN   -8.14%    
VIR        10.39% 
• View Complete Report
   



Clinical Study

Aligos Therapeutics to Present Eight Research s at EASL Congress 2025 Amidst Market Performance Challenges,

Published Thu, Apr 24 2025 10:10 AM UTC

Aligos Therapeutics Sets Stage for EASL Congress 2025 with Eight Accepted s SOUTH SAN FRANCISCO, Calif. April 23, 2025 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company dedicated to enhancing patient outcomes through advanced therapies targeting liver and viral diseases, today announced that eight of its research abstracts have been accep...
Shares

Aligos Therapeutics Leverages Stock Options to Attract Top Talent Amidst Growing Biopharma Landscape,

Published Fri, Mar 14 2025 12:00 PM UTC

Aligos Therapeutics Moves Forward with Strategic Inducement Grants to Attract TalentSOUTH SAN FRANCISCO, Calif. Aligos Therapeutics, Inc. (Nasdaq: ALGS), a promising player in the clinical-stage biopharmaceutical sector, is actively enhancing its talent pool through strategic stock incentive grants, as detailed in a recent press release. On March 14, 2025, Aligos announce...
Stock Market Announcement

Aligos Therapeutics Continues Strategic Growth with New Inducement Grants Amid Booming Stock Performance

Published Fri, Dec 13 2024 1:00 PM UTC

SOUTH SAN FRANCISCO, Calif. In a clear sign of its ongoing strategic growth and commitment to attracting top talent, Aligos Therapeutics, Inc. (Nasdaq: ALGS) recently announced the grant of a non-qualified stock option to a newly hired employee. This latest inducement grant, amounting to 5,500 shares, was approved by the Compensation Committee of the Company’s Board of D...
Clinical Study

Pioneering Progress & Profound Loss Aligos Therapeutics Highs and Lows in Liver Research 2024,

Published Tue, Nov 19 2024 6:31 PM UTC

Aligos Therapeutics Advances Hepatic Therapeutics with Landmark Discoveries in 2024 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical organization pioneering the landscape of liver and viral disease therapeutics, marked a significant year of progress in 2024 with impactful presentations and poignant moments at major international hepatitis research...
Shares

Aligos Therapeutics Bolsters Its Ranks with Stock Options Amid MASH Breakthroughs,

Published Fri, Oct 11 2024 12:00 PM UTC

Aligos Therapeutics Expands Talent Pool with Strategic Stock Options Amid MASH Treatment Innovations By , Contributor SOUTH SAN FRANCISCO, Calif. Oct. 11, 2024 In a bold move signaling its commitment to fostering innovation in the biopharmaceutical sector, Aligos Therapeutics, Inc. has announced substantial stock option grants to new employees as part of its strategic gro...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 12.96
Price to Sales (Expected) -
Price to Book 1.92
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.8
Working Capital Ratio 3.04
Leverage Ratio (MRQ) 1.03
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -8.79 $
Revenues (TTM) 0.45 $
Cash Flow (TTM) -
Cash 5.28 $
Book Value 3.06 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 57,378
Net Income per Employee (TTM) -1,101,476
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.05

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -951.55 %
Net Margin (MRQ) -814.13 %
Net Cash Flow Margin (MRQ) 414.88 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Aligos Therapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.